More info about Nacer Lounis

On-campus

Company
Janssen Pharmaceutica

Function
Senior Principal Scientist

More info about Tine de Marez

On-campus

Company
Johnson & Johnson

Function
Senior Director, Compound Development Team Leader TB

More info about Erik Niks

On-campus

Company
Leiden University Medical Center

Function
Neurologist - Pediatric neurologist

More info about Ad Sitsen

On-campus

Company
ClinPharMed Consultancy for Drug Development

Function
Owner

Prof. Dr J.M. Ad Sitsen completed his pharmaceutical studies at the State University of Utrecht in The Netherlands in March 1970 and obtained a Ph.D. in medicinal chemistry two years later. After having fulfilled his compulsory military service with the Royal Dutch Navy he began his medical studies in 1974, which he completed in 1980. He then specialized in pharmacology at the Rudolf Magnus Institute of the Medical Faculty of the University of Utrecht and subsequently trained for two years in internal medicine at the Academic Hospital of the same Medical Faculty. In 1984 he joined N.V. Organon, a business unit of Akzo Nobel, and has been involved in the clinical development of Remeron® from the beginning and also many other compounds. He retired in 2004 and now acts as a consultant to pharmaceutical companies. He was a member of the Dutch Health Council and a (part-time) professor of clinical pharmacology at the Medical Faculty of the Utrecht University, Utrecht, The Netherlands. He has published approximately 100 research articles and reports and was editor of volume 6 of the Handbook of Sexology: The Pharmacology and Endocrinology of Sexual Function (Amsterdam:Elsevier, 1988). He is co-editor of the Handbook of Anxiety and Depression: A biological Approach (New York: Marcel Dekker, 1994) and editor-in-chief of the major Dutch language textbook of pharmacology. Specialties: assessment of toxicological data, design of first time in man studies, clinical pharmacology, drug development, medical writing

More info about Paul Stoffels

Company
Galapagos

Function
CEO

Paul Stoffels joined Galapagos as Chief Executive Officer in April 2022, and is an executive member and the Chairman of our Board of Directors since 26 April 2022. He also is a member of the Executive Committee at Galapagos. Prior to that, he was Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson where he set the company’s wide innovation agenda and led its pharmaceutical R&D-pipeline, as well as other external initiatives. Before that, he was worldwide Chairman of Pharmaceuticals of Johnson & Johnson which, under his leadership, significantly rejuvenated its product pipeline and adopted a transformational R&D-operating model, which resulted in the launch of 25 innovative medicines across the globe. Dr. Stoffels joined Johnson & Johnson in 2002, following the acquisition of Virco and Tibotec, where he was Chief Executive Officer and Chairman respectively, and where he led the development of several breakthrough products for the treatment of HIV. Dr. Stoffels also is a member of the Supervisory Board of Philips Healthcare in the Netherlands.

More info about Marcel Kenter

On-campus

Company
Paul Janssen Futurelab Leiden

Function
Director

Marcel Kenter studied molecular biology at Leiden University and obtained his PhD degree for his work on the genetics of the primate Major Histocompatibility Complex (Mhc) in the immunology department of Prof Johannes van Rood (Leiden University Medical Center (LUMC), the Netherlands). He continued his post-doctoral work on virology at the department of Prof. Ab Osterhaus (Erasmus Medical Center, the Netherlands) and on gene therapy at the Daniel den Hoed Cancer Center. In 1999, he became the first executive director of the Central Committee Involving Human Subjects (CCMO); the competent authority for clinical trials with medicinal products in the Netherlands. He has been director of Paul Janssen Futurelab Leiden since 2015.  

More info about Koen Andries

On-campus

Company
Janssen Pharmaceutica NV

Function
VP Scientific Fellow Infectious Diseases Discovery

Dr Koen Andries (1951) studied Veterinary Sciences and obtained his PhD at the University of Ghent, Belgium. He joined the team of Dr. Paul Janssen in 1982.  Using cell-based assays in search of antiviral compounds, his team discovered nanomolar inhibitors of uncoating of rhinoviruses, picomolar inhibitors of fusion of respiratory syncytial virus and several non-nucleoside reverse transcriptase inhibitors of HIV (TIBO’s, alpha-APA’s, and DAPY’s) with high activity against wild-type and resistant HIV-1 strains. Two of these became approved drugs: etravirine - intelence® and rilpivir - edurant®, and a third one is being developed as a microbicide in a vaginal ring to prevent HIV infection (dapivirine). Dr Andries also led the team that discovered R207910/TMC207 (bedaquiline – sirturo®), a first in-class new anti-tuberculosis drug, and its unique mechanism of action. Bedaquiline is the first molecule with specific activity against the ATP synthase, one of the most fundamental enzymes in biology, and the first antibiotic known to interfere with the generation of energy. He grandfathered bedaquiline from discovery to early development and eventually full development as the microbiology leader. He authors 173 papers, 179 abstracts and 32 patents, and is Professor emeritus at the University of Antwerp.

More info about Andreas Wallnöfer

On-campus

Company
BioMed Partners Venture Capital (former Head of Clinical Research & Exploratory Development at F. Hoffmann-La Roche Ltd.)

Function
General Partner

More info about André Elferink

On-campus

Company
Dutch Medicines Evaluation Board

Function
Clinical epidemiologist

I am a physician with a neurological and methodological background (clinical epidemiologist). Since 1992  I work as a senior clinical assessor at the Dutch Medicines Evaluation Board. As a clinical assessor I advice the Dutch Medicines Evaluation Board and the European Committee for Proprietary Medicinal Products whether a medicinal agent may be approved for a claimed indication and if so, under which conditions. The MEB I started as a generalist but may main field of interest is neurology.  In this context  I am member of the CNS-Working party involved in setting up regulatory Scientific Guidelines. Within the neurology my special fields of interest are Multiple sclerosis, Parkinson's Disease and Epilepsy. As generalist I  became member of the Scientific Advice Working party in 2012.

More info about Hans-Georg Eichler

Company
European Medicines Agency

Function
Senior Medical Officer

More info about Johan Garssen

Company
Danone/Nutricia Research

Function
Director Immunology Platform

More info about Rick Kuntz

Company
Medtronic

Function
Former Senior Vice President and Chief Scientific, Clinical and Regulatory Officer

Dr. Rick Kuntz was Medtronic’s Senior Vice President, Chief Medical and Scientific Officer of Medtronic and served as a member of the Company’s Executive Committee until 2021. In this role, Kuntz oversaw the company’s medical affairs, health policy and reimbursement, clinical research activities, and corporate technology.

More info about Oliver Bisazza

Company
Medtronic

Function
Former Director Regulatory Policy

More info about Richard Shull

Company
Shell

Function
Head of Deal Structuring and Trading Fundamentals